Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Hydrocortison cream
Hydrocortison · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Sinecort cream | DEVICE | Application over 29 days |
| Hydrocortison cream | DRUG | Application over 29 days |
| Untreated skin | OTHER | - |
Inclusion Criteria: * Male or female Caucasians aged between 18 and 65 years * Patients with mild AD presenting a scoring AD (SCORAD) rating between 3-25 * Skin type I - IV according to Fitzpatrick * Acute AD symptoms on each assessment areas (local SCORAD \>/=3 and \<= 12) * Acute symptom of pruri...
Top 20 of 26 competitors
Hydrocortison is a small molecule being developed for atopic dermatitis, a form of eczema. It is a topical therapy studied in adults with the condition. Development is at Phase 2, so it is investigational and not yet an approved treatment for atopic dermatitis.
Hydrocortison targets NR3C1, the glucocorticoid receptor, and acts as an agonist at that receptor. Agonist activity at NR3C1 is the mechanism by which the drug is intended to act in atopic dermatitis. The compound is a small molecule administered as a topical cream.
Hydrocortison is being developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor behind the clinical development program for the drug in atopic dermatitis.
Hydrocortison is in Phase 2 clinical development for atopic dermatitis. It is an investigational drug and has not been approved for marketing. One Phase 2 trial has been completed, and no trials are currently listed as active.
Hydrocortison has been studied in the Sinecort Pilot Efficacy Study, registered as NCT00980135. That Phase 2 trial was completed in Germany and enrolled 40 adults with atopic dermatitis. It was randomized and controlled, and it was not double blinded.
Yes, Hydrocortison cream is another name for Hydrocortison. Both names refer to the same topical small molecule developed by Bayer AG for atopic dermatitis, so searches using either name point to the same investigational asset.